Quality · Access · Hope
Countries

🇨🇭 Country Profile

Switzerland

Fast-growing pharmaceutical trade with Switzerland

🇨🇭 $67.7M
Dual-source profile. Both series show finished pharmaceutical products aligned to calendar year (Jan–Dec). Swiss Customs records what Switzerland imports from India. DGCIS records what India exports to Switzerland. Category and product detail from DGCIS.
$67.7M
Scale
Switzerland's healthcare system receives $67.7M in Indian pharmaceutical products each year — affordable, quality medicine.
74%
Medicine
Primarily medicine ingredients (74%), supplemented by medicines and surgical & hospital supplies.
5.5×
Trajectory
Rapid expansion: Switzerland's imports of Indian pharmaceutical products have grown 5.5× over the past decade, from $12.2M to $67.7M.
Context
Part of India's pharmaceutical supply network across Europe.
✦
Impact
Indian pharmaceutical companies have both exported to and invested directly in Switzerland — building trade and operational presence.
Export Trend Swiss Customs CY DGCIS India-reported
Beyond Finished Medicines DGCIS CY 2014–2025

Additional pharmaceutical categories from DGCIS — APIs, surgical, herbal, and more

Category Mix — FY 2025–26 DGCIS
Medicine Ingredients $51.8M (74.1%) Medicines $13.1M (18.8%) Surgical & Hospital Supplies $4.3M (6.2%) Traditional & Herbal $0.56M (0.8%) Vaccines $0.10M (0.1%)
Top Products — FY 2025–26 DGCIS
Active Pharmaceutical Ingredients DGCIS India-side

India also supplied $62.7M in active pharmaceutical ingredients and bulk drugs to Switzerland in 2025 (India-reported, DGCIS).

Indian Pharma Investment in Switzerland Source: RBI ODI Data

Total RBI-approved ODI commitments by Indian pharmaceutical companies into Switzerland: $9.0B across 265 filings (2011-2026).

Global Pharma Thrives in India Source: OPPI / Annual Reports

The relationship flows both ways. Swiss pharmaceutical companies are among the largest investors in India's health ecosystem — operating manufacturing plants, R&D centres, and clinical trial networks across the country.

Roche
$71B global revenue
100,000 employees
Ocrevus (Neuroscience) · Hemlibra (Haematology) · Vabysmo (Ophthalmology)
Novartis
$58B global revenue
Entresto (Cardiovascular) · Kisqali (Oncology) · Cosentyx (Immunology)